These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14654935)

  • 1. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
    Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
    Del Bufalo D; Trisciuoglio D; Scarsella M; Zangemeister-Wittke U; Zupi G
    Oncogene; 2003 Nov; 22(52):8441-7. PubMed ID: 14627985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
    McCarty MF
    Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
    Rashmi R; Kumar S; Karunagaran D
    Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
    Olie RA; Zangemeister-Wittke U
    Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
    Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
    Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
    Jackson JK; Gleave ME; Gleave J; Burt HM
    Angiogenesis; 2005; 8(3):229-38. PubMed ID: 16308731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.